aibio
Listings ·
Zhengye Biotechnology regains Nasdaq bid price compliance
Nasdaq's August 5, 2026 letter says the Class A ordinary shares closed at $1.00 or more for ten straight business days. The shares stay on the Nasdaq Capital Market.
ZYBT Zhengye Biotechnology Holding Limited
Zhengye Biotechnology Holding (ZYBT) news ZYBT Nasdaq notice news
Latest Zhengye Biotechnology Holding news
- Listings
Zhengye Biotechnology shareholders approve share reclassification and consolidation
All five resolutions passed at the March 24, 2026 annual meeting, including a share reclassification and a share consolidation.
- Distress
Zhengye Biotechnology files late-filing notice, auditor needs more time on 20-F
The company says it is still compiling information for its annual report for the year ended December 31, 2024.
Zhengye Biotechnology Holding annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $16.6 million | $25.5 million |
| Research and development | $2.6 million | $1.8 million |
| Net income (loss) | -$10.0 million | $1.6 million |
| Cash from operations | $1.9 million | $5.6 million |
| Cash and equivalents | $7.2 million | $2.5 million |
| Short-term investments | $223,000 | $197,000 |
Questions about Zhengye Biotechnology Holding
Has Zhengye Biotechnology Holding received a Nasdaq deficiency notice?
Our latest story on this, dated Apr 29, 2025: "Zhengye Biotechnology files late-filing notice, auditor needs more time on 20-F". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Zhengye Biotechnology Holding?
Zhengye Biotechnology Holding Limited trades under the ticker ZYBT on NASDAQ.
Where is Zhengye Biotechnology Holding listed?
Zhengye Biotechnology Holding Limited is listed on NASDAQ.
What is the SEC CIK of Zhengye Biotechnology Holding?
The SEC Central Index Key (CIK) for Zhengye Biotechnology Holding Limited is 1975641. Its filings are on SEC EDGAR.
How many shares does Zhengye Biotechnology Holding have outstanding?
47,391,376 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-28.
Which country or territory is Zhengye Biotechnology Holding listed under?
Our directory records Zhengye Biotechnology Holding Limited under China.
What does Zhengye Biotechnology Holding do?
Our directory classifies Zhengye Biotechnology Holding Limited as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Zhengye Biotechnology Holding?
The ISIN recorded for Zhengye Biotechnology Holding Limited is KYG989MS1016.
Does aibio.space cover Zhengye Biotechnology Holding?
aibio.space lists Zhengye Biotechnology Holding Limited among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Zhengye Biotechnology Holding incorporated?
SEC records list its state or country of incorporation as F4.
What was Zhengye Biotechnology Holding's revenue last year?
$16.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Zhengye Biotechnology Holding profitable?
Zhengye Biotechnology Holding Limited reported a net loss of $10.0 million for the fiscal year ended Dec 31, 2025, and generated $1.9 million of cash from operations, per its annual report to the SEC.
How much does Zhengye Biotechnology Holding spend on research and development?
$2.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Zhengye Biotechnology Holding have?
$7.4 million in cash and short-term investments at Dec 31, 2025, per its 20-F.
What is the latest Zhengye Biotechnology Holding (ZYBT) stock news?
Our latest story on Zhengye Biotechnology Holding, dated Aug 6, 2026: "Zhengye Biotechnology regains Nasdaq bid price compliance". Nasdaq's August 5, 2026 letter says the Class A ordinary shares closed at $1.00 or more for ten straight business days. The shares stay on the Nasdaq Capital Market. Source.
Investor discussion: Zhengye Biotechnology Holding
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
- Listings
Reported a reverse stock split. SEC Form 6-K. Source
- Listings
Reported a reverse stock split. SEC Form 6-K. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 20-F. Source
Stock chart
SEC filings and registration
- SEC name
- Zhengye Biotechnology Holding Ltd
- CIK
- 1975641
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- ZYBT (Nasdaq)
- State or country of incorporation
- F4
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Business address
- NO.1 LIANMENG STREET, JILIN ECONOMIC &, JILIN
- Phone
- 86-13844801919
- Shares outstanding
- 47,391,376 as of 2025-12-31 (20-F filed 2026-04-28)
Recent filings
Listing details
- Company
- Zhengye Biotechnology Holding Limited
- Ticker
- ZYBT
- Listing
- NASDAQ
- Country or territory
- China
- Business scope
- Biotechnology
- ISIN
- KYG989MS1016
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction